Profile data is unavailable for this security.
About the company
WuXi AppTec Co., Ltd. is a China-based investment holding company principally engaged in the provision of new drug research and development (R&D), production and supporting services, as well as related technology platform services. The Company is mainly engaged in the discovery, development and production of small molecule drugs, cell therapies and gene therapies, as well as providing testing services for medical devices. The Company mainly conducts its businesses through four segments, including China-based Laboratory Services segment, Contract Manufacturing organization/contract development and manufacturing organization services (CMO/CDMO services) segment, US-based Laboratory Services segment and Clinical Research segment.
- Revenue in HKD (TTM)42.34bn
- Net income in HKD11.26bn
- Incorporated2000
- Employees41.12k
- LocationWuXi AppTec Co Ltd228 Fute Zhong RoadWaigaoqiao Free Trade ZoneSHANGHAI 200131ChinaCHN
- Phone+86 2 150461000
- Fax+86 2 150463093
- Websitehttp://www.wuxiapptec.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Wantai Biolog Pha Ent Co Ltd | 3.63bn | 138.12m | 89.17bn | 3.84k | 700.89 | 6.46 | -- | 24.56 | 0.0933 | 0.0933 | 2.68 | 10.12 | 0.2058 | 0.8371 | 0.8434 | 878,660.70 | 0.7531 | 24.08 | 0.9228 | 31.80 | 76.97 | 85.18 | 3.66 | 34.95 | 3.84 | -- | 0.0258 | 9.88 | -50.73 | 41.18 | -73.65 | 33.61 | 36.35 | -- |
| Torrent Pharmaceuticals Ltd | 10.04bn | 1.55bn | 89.66bn | 13.57k | 57.84 | 13.97 | 38.88 | 8.93 | 48.94 | 48.94 | 317.04 | 202.56 | 0.7135 | 1.19 | 5.66 | -- | 11.01 | 8.34 | 17.25 | 13.03 | 74.96 | 72.01 | 15.44 | 13.17 | 0.6141 | 7.23 | 0.3697 | 53.04 | 11.52 | 6.93 | 32.99 | 30.57 | -8.16 | 26.93 |
| Shionogi & Co Ltd | 21.27bn | 7.92bn | 90.24bn | 4.96k | 11.16 | 1.43 | 10.32 | 4.24 | 557.64 | 557.64 | 1,499.18 | 4,357.54 | 0.3189 | 0.9378 | 3.75 | 87,735,430.00 | 11.77 | 12.57 | 13.40 | 14.24 | 86.76 | 84.43 | 36.91 | 37.91 | 5.37 | -- | 0.0092 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
| Dr Reddy's Laboratories Ltd | 26.22bn | 5.22bn | 94.75bn | 24.83k | 18.17 | 3.58 | 14.36 | 3.61 | 334.61 | 334.61 | 1,680.33 | 1,696.70 | 0.7874 | 1.46 | 3.67 | -- | 15.68 | 11.37 | 21.05 | 16.02 | 70.69 | 66.52 | 19.91 | 14.63 | 1.92 | 41.27 | 0.0662 | 16.40 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Eisai Co Ltd | 36.27bn | 2.07bn | 96.17bn | 11.07k | 44.85 | 2.17 | 23.65 | 2.65 | 147.86 | 147.86 | 2,586.27 | 3,050.54 | 0.5583 | 0.986 | 4.50 | 67,023,670.00 | 3.30 | 5.29 | 4.36 | 7.16 | 79.06 | 76.91 | 5.90 | 8.68 | 1.80 | -- | 0.1506 | 74.13 | -0.3561 | 2.90 | -23.50 | -7.72 | -2.11 | 1.30 |
| Hansoh Pharmaceutical Group Company Ltd | 10.87bn | 3.53bn | 99.24bn | 9.12k | 28.62 | 3.57 | 25.32 | 9.13 | 0.5842 | 0.5842 | 1.81 | 4.68 | 0.3206 | 2.02 | 3.00 | 1,191,260.00 | 10.40 | 11.58 | 12.24 | 13.98 | 89.78 | 90.78 | 32.44 | 29.28 | 4.12 | -- | 0.143 | 12.75 | 7.69 | 5.52 | 26.85 | 11.49 | -10.45 | -- |
| Zydus Lifesciences Ltd | 18.30bn | 3.59bn | 100.94bn | 23.03k | 28.27 | 5.44 | 23.47 | 5.52 | 37.91 | 38.14 | 193.16 | 197.11 | 0.7103 | 1.82 | 4.06 | -- | 13.92 | 9.05 | 19.29 | 14.01 | 68.14 | 62.16 | 19.60 | 14.33 | 1.51 | 22,696.00 | 0.0351 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Divi's Laboratories Ltd | 7.34bn | 1.50bn | 112.79bn | 16.95k | 75.32 | 8.88 | 60.92 | 15.36 | 60.27 | 60.27 | 295.54 | 511.21 | 0.5246 | 1.01 | 3.97 | -- | 10.70 | 16.55 | 11.62 | 18.22 | 60.11 | 57.95 | 20.40 | 26.38 | 5.08 | -- | 0.0002 | 34.33 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
| Cipla Ltd | 24.12bn | 3.86bn | 113.35bn | 26.62k | 29.39 | 4.53 | 23.26 | 4.70 | 51.02 | 51.02 | 319.08 | 330.77 | 0.829 | 1.70 | 5.84 | -- | 13.37 | 10.09 | 16.16 | 12.40 | 65.78 | 59.69 | 16.12 | 12.66 | 2.71 | 58.30 | 0.0205 | 20.79 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| WuXi AppTec Co Ltd | 42.34bn | 11.26bn | 121.83bn | 41.12k | 8.03 | 1.50 | -- | 2.88 | 3.82 | 3.82 | 14.41 | 20.40 | 0.55 | 6.49 | 4.14 | 1,029,656.00 | 14.77 | 12.21 | 18.68 | 15.58 | 40.28 | 38.18 | 26.86 | 22.52 | 2.09 | 69.11 | 0.1124 | 28.20 | 2.51 | 33.22 | 21.33 | 36.44 | 21.40 | 32.02 |
| Beigene Ltd | 21.57bn | -6.12bn | 133.58bn | 10.00k | -- | 4.88 | -- | 6.19 | -4.55 | -4.55 | 15.80 | 19.30 | 0.4753 | 1.87 | 7.42 | -- | -13.50 | -26.72 | -18.48 | -33.85 | 74.76 | 83.19 | -28.39 | -120.76 | 1.84 | -- | 0.2339 | -- | 73.65 | 65.47 | 56.00 | -- | 33.46 | -- |
| Astellas Pharma Inc | 78.41bn | 833.40m | 139.67bn | 14.75k | 167.97 | 1.77 | 16.33 | 1.78 | 9.40 | 9.40 | 892.49 | 890.07 | 0.5322 | 1.38 | 3.33 | 108,694,000.00 | 0.5657 | 4.59 | 0.8492 | 6.61 | 81.76 | 80.53 | 1.06 | 7.98 | 0.7358 | 22.28 | 0.3866 | 86.61 | 5.60 | 4.19 | -82.73 | -40.17 | 9.62 | 13.00 |
Data as of Jun 26 2024. Currency figures normalised to WuXi AppTec Co Ltd's reporting currency: Hong Kong Dollar HKD
25.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Schroder Investment Management (Hong Kong) Ltd.as of 29 May 2024 | 16.81m | 4.34% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 15.50m | 4.01% |
| Capital International Ltd.as of 31 Mar 2024 | 14.09m | 3.64% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 12.44m | 3.21% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 10.60m | 2.74% |
| Qatar Investment Authority (Investment Management)as of 30 Jun 2023 | 8.35m | 2.16% |
| BlackRock Fund Advisorsas of 13 Jun 2024 | 7.61m | 1.97% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 5.14m | 1.33% |
| BlackRock Advisors (UK) Ltd.as of 13 Jun 2024 | 4.66m | 1.21% |
| Hang Seng Investment Management Ltd.as of 07 Jun 2024 | 3.96m | 1.02% |
More ▼
Data from 31 Dec 2023 - 03 Jun 2024Source: FactSet Research Systems Inc.
